

Why Pharmaceutical Clinical Trials Struggle to Succeed?

Cyntegrity's Presentation for Potential Investors


Artem Andrianov, PhD, MBA

Cyntegrity, 2015



WHO ARE WE?

WHO ARE WE?



- > Team with 10+ years of experience in clinical data analysis
- > 20+ analyzed clinical trials
- > Over 100+ supported clinical trials for big pharma
- > OverRead(Central Lab) and Data Cleaning services
- Scientific research together with academia
- Partnerships with local and global CROs

<mark>yn</mark>tegrity

OUR STRATEGY



Our Partners and Customers in RbM already







German Government Research Funding

Cyntegrity - winner of the Hessen Model-Project Funding with the Project "Process Innovation in Clinical Trial Monitoring"







Hessens Zukunft 6

WHAT PROBLEM WE TACKLE?


Cost of Outsourcing by Function In Clinical Research



FDA Success by Phase (LOA=Likelihood Of Approval)



Clinical Trial-Challenges



⁵Linda Martin KMR, Bernstein R&D Conference 2011, cited in Roche 1H2011 results presentation

R&D returns have nearly halved over the last 10 years.

Risk Potential and Its Assessment

- Potential risk may arise
 from the budget, milestones
 and activities
- The probability of
 - occurrence can be
 - estimated
- Usually an incoming risk
 affects the time course and
 thus to the costs


Project Manage ment

- budget,
- timelines,
- targets

Research

- research goal
- statistical significance
- prove of efficacy


Internal and External Risks




Clinical Trials Challenges




Right Actions in Right Time




WHAT SOLUTION WE PROVIDE?



Key Risk Defense Strategy




Control of Clinical "Data Noise"







Equality



Systematic Error

Precision




Equality


Technology plays a critical role in effective risk-based monitoring. However, the monitoring team is equally important.



Result 1: Site Visits Optimization



Result 2: Absolute Data Quality








Result 3: Continuous Improvement



Result 3: Effective Communication and Knowledge Sharing within Team and among Trial Groups

🗩 Local Ti	cket Chat	~ *	
	ABOUT A MINUTE AGO O Hi Jane, could you	YOU help me.	
	LESS THAN A MINUTE AGO O I would need a nan Investigator for		
		~	
1000			

bject ck a patient signature in patient agreement is different to writing in the CRFs. ck if patient agreement form is available. ck if returned investigational drug is very clean for all ents and has no signs of use. wn correlation between age and blood pressure could not etected. ree text and no comments found in questionaires. tries	Priority ◊ 3 3 3 3 2	Search [AssignedTo € Ms. Mandy M. Young Ms. Courtney E. Payne Ms. Wondy G. Cox Mr. Revin J. Salazar Ms. Debra D. Kaplan ← Previo	CreatedAt € 5/6/2014 1:30 PM 10 11 12	Actions ♦ Details Details Details Details Details Details 3
k a patient signature in patient agreement is different to dwriting in the CRFs. ck if patient agreement form is available. ck if returned investigational drug is very clean for all ents and has no signs of use. wn correlation between age and blood pressure could not etected. ree text and no comments found in questionaires.	3 3 3 3	Ms. Mandy M. Young Ms. Courtney E. Payne Ms. Wendy G. Cox Mr. Kevin J. Salazar Ms. Debra D. Kaplan	5/6/2014 1:30 PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM	Details Details Details Details Details
dwriting in the CRFs. ck if patient agreement form is available. ck if returned investigational drug is very clean for all ents and has no signs of use. wn correlation between age and blood pressure could not etected. ree text and no comments found in questionaires.	3 3 3	Young Ms. Courtney E. Payne Ms. Wendy G. Cox Mr. Kevin J. Salazar Ms. Debra D. Kaplan	PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM	Details Details Details Details
ck if returned investigational drug is very clean for all ents and has no signs of use. wn correlation between age and blood pressure could not etected. ree text and no comments found in questionaires.	3	E. Payne Ms. Wendy G. Cox Mr. Kevin J. Salazar Ms. Debra D. Kaplan	PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM	Details Details Details
ents and has no signs of use. wn correlation between age and blood pressure could not etected. ree text and no comments found in questionaires.	3	Cox Mr. Kevin J. Salazar Ms. Debra D. Kaplan	PM 5/6/2014 1:30 PM 5/6/2014 1:30 PM	Details Details
etected. ree text and no comments found in questionaires.		Salazar Ms. Debra D. Kaplan	PM 5/6/2014 1:30 PM	Details
	2	Kaplan	PM	
tries		← Previo	us 1 2	3 Next→
Î				



Applied Statistical Methods



- Distributions and Properties
 Variables
- ✓ Proportion of missing values
- ✓ Means
- Global variances within patient variances
- ✓ Proportion of week days
- ✓ Proportions of Outliers
- ✓ Correlation between variables
- ✓ Event counts

Technological Innovation Science Orientation

WHAT MAKES US UNIQUE?

Umbrella Principle


Undependability

Willingness to share

Market Potential

Cyntegrity operates on the Healthcare Information Services, with the market capitalization **\$40 Bn**, with the forecast of CAGR 22.5% only in U.S. during 2012-2014.

Sector:	Technology		
Industry:	Healthcare Information Services		
Industry Statistics			
Price / Earnings:	55.3		
Price / Book:	20.7		
Net Profit Margin (mrq):	8.8%		
Price To Free Cash Flow (mrq):	62.9		
Return on Equity:	10.6%		
Total Debt / Equity:	63.6		




Number of registered Studies over time. Source: ClinicalTrials.gov

CAGR – Compound annual growth rate Source: U.S. Healthcare IT Market Analysis (Oct, 2011) <u>http://www.rncos.com/Report/IM321_fig.htm</u> Source: yahoo finance 24. Nov 2013 (<u>http://biz.yahoo.com/ic/825.html</u>)

Who is our Customer?

Client	Value Proposition
Contract research organization (CROs)	Competitive advantage on the market in offering advanced quality assurement as an additional service for pharmaceutical corporations.
	Additionally optimisation & reduction of the costs of clinical monitoring.
Pharmaceutical Organizations	Reduction of the dirty data risks, i.e. risk of damaging reputation, new quality standard within industry.
	Service of sanity checks can become required in the preparation to FDA audits, minimizing the risks of audit findings.
Biotech Companies	Optimization of clinical monitoring costs, mitigating the risks with later identification of problem zones.

Proven Value for Customer





Irving Fisher (1867-1947)